LifeSteps Financial Inc. Cuts Stake in Johnson & Johnson (NYSE:JNJ)

LifeSteps Financial Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,193 shares of the company’s stock after selling 67 shares during the period. LifeSteps Financial Inc.’s holdings in Johnson & Johnson were worth $759,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the business. James J. Burns & Company LLC raised its holdings in Johnson & Johnson by 401.4% in the second quarter. James J. Burns & Company LLC now owns 8,022 shares of the company’s stock worth $1,173,000 after purchasing an additional 6,422 shares in the last quarter. Phoenix Wealth Advisors raised its stake in shares of Johnson & Johnson by 4.1% during the 2nd quarter. Phoenix Wealth Advisors now owns 22,120 shares of the company’s stock worth $3,233,000 after acquiring an additional 862 shares in the last quarter. SteelPeak Wealth LLC lifted its position in Johnson & Johnson by 21.6% during the second quarter. SteelPeak Wealth LLC now owns 71,027 shares of the company’s stock valued at $10,381,000 after acquiring an additional 12,618 shares during the last quarter. Hengehold Capital Management LLC boosted its stake in Johnson & Johnson by 26.1% in the second quarter. Hengehold Capital Management LLC now owns 24,086 shares of the company’s stock valued at $3,520,000 after acquiring an additional 4,984 shares in the last quarter. Finally, 180 Wealth Advisors LLC grew its holdings in Johnson & Johnson by 1.1% in the second quarter. 180 Wealth Advisors LLC now owns 13,258 shares of the company’s stock worth $1,985,000 after purchasing an additional 150 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $0.62 during trading hours on Thursday, reaching $159.10. The company had a trading volume of 7,237,481 shares, compared to its average volume of 7,355,802. The firm has a market cap of $382.90 billion, a PE ratio of 9.90, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.39. The business’s 50 day moving average price is $151.88 and its 200-day moving average price is $153.10. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same period in the prior year, the firm posted $2.80 earnings per share. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. Research analysts forecast that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.12%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on JNJ. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 8th. Bank of America decreased their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Finally, Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.